Adenosine A2A antagonists in Parkinson's disease: what's next?

Current Neurology and Neuroscience Reports
Patrick Hickey, Mark Stacy

Abstract

Parkinson's disease (PD) is the second most prevalent neurodegenerative disorder, affecting up to 10 million people worldwide. Current treatment primarily involves symptom management with dopaminergic replacement therapy. Levodopa remains the most effective oral treatment, although long-term use is associated with complications such as wearing off, dyskinesias, and on-off fluctuations. Non-dopaminergic medications that improve PD symptoms and motor fluctuations are in demand. Adenosine A2A receptors are abundantly expressed within the basal ganglia and offer a unique target to modify abnormal striatal signaling associated with PD. Preclinical animal models have shown the ability of adenosine A2A receptor antagonists to improve PD motor symptoms, reduce motor fluctuations and dyskinesia, as well as protect against toxin-induced neuronal degeneration. Both istradefylline and preladenant have demonstrated moderate efficacy in reducing off time in PD patients with motor fluctuations. The safety and efficacy of this class of compounds continues to be defined and future studies should focus on non-motor symptoms, dyskinesias, and neuroprotection.

References

Sep 16, 1991·Neuroscience Letters·S FerréK Fuxe
Jul 1, 1990·Trends in Neurosciences·M R DeLong
Oct 1, 1989·Trends in Neurosciences·R L AlbinJ B Penney
May 2, 1994·European Journal of Pharmacology·T KandaJ Nakamura
May 1, 1996·Journal of Neurochemistry·M KurokawaY Kuwana
May 20, 2000·JAMA : the Journal of the American Medical Association·G W RossL R White
Oct 21, 2000·European Journal of Pharmacology·L HalldnerB B Fredholm
Mar 21, 2002·Journal of Neurochemistry·Ken IkedaYoshihisa Kuwana
Jul 6, 2002·European Journal of Pharmacology·Annalisa PinnaMicaela Morelli
Aug 13, 2003·Neurology·W Bara-JimenezT N Chase
Aug 13, 2003·Neurology·Robert A HauserUNKNOWN Istradefylline US-001 Study Group
Oct 3, 2003·Trends in Neurosciences·Eric A Newman
Nov 16, 2004·Trends in Neurosciences·Leif Hertz, H Ronald Zielke
Dec 17, 2004·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Elena BastiaMichael A Schwarzschild
Aug 12, 2005·Journal of Neurochemistry·Josep SauraJoan Serratosa
Dec 31, 2005·Journal of Integrative Neuroscience·Sergi FerréRodrigo Cunha
Oct 13, 2006·Trends in Neurosciences·Michael A SchwarzschildMicaela Morelli
Dec 29, 2006·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Danqing XiaoMichael A Schwarzschild
Apr 11, 2007·Archives of Neurology·Dana B HancockWilliam K Scott
May 25, 2007·European Journal of Clinical Nutrition·K SääksjärviS Männistö
Jul 25, 2007·Progress in Neurobiology·S N SchiffmannS Ferré

❮ Previous
Next ❯

Citations

Dec 7, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Albert Y Hung, Michael A Schwarzschild
Jul 15, 2015·Expert Opinion on Emerging Drugs·Jonathan Tomas Lockwood, Gary Remington
Feb 14, 2015·Expert Opinion on Drug Safety·Thomas Müller
Jun 10, 2015·SAR and QSAR in Environmental Research·E PourbasheerM R Ganjali
Mar 29, 2014·Expert Opinion on Pharmacotherapy·Santiago Perez-Lloret, Marcelo Merello
Sep 21, 2018·Expert Opinion on Pharmacotherapy·Margherita TortiFabrizio Stocchi
Jun 17, 2014·Medicinal Research Reviews·Antoni CortésVicent Casadó
Mar 21, 2019·Expert Review of Neurotherapeutics·Khashayar DashtipourKelly E Lyons
Jan 2, 2021·Frontiers in Pharmacology·Felipe PatricioIlhuicamina Daniel Limón
Feb 22, 2021·Cellular Signalling·Samantha M McNeillLauren T May
Feb 7, 2018·Journal of the Neurological Sciences·Keisuke SuzukiKoichi Hirata

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal ganglia in Parkinson's disease (MDS)

The basal ganglia is comprised of the neostriatum, the external and internal pallidal segments, the subthalamic nucleus, the substantia nigra pars reticulata, and the pars compacta of the substantia nigra. The basal ganglia circuitry is responsible for the correct execution of voluntary movements and is implicated in Parkinson's disease. Here is the latest research investigating the basal ganglia in Parkinson's disease.

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Related Papers

Movement Disorders : Official Journal of the Movement Disorder Society
Yoshikuni MizunoJapanese Istradefylline Study Group
Expert Opinion on Pharmacotherapy
Ariane Park, Mark Stacy
Expert Opinion on Drug Metabolism & Toxicology
Nikoletta SzabóLászló Vécsei
© 2021 Meta ULC. All rights reserved